Trial Profile

A prospective, single-center trial evaluating combination of sintilimab/nivolumab (NIVO) Q3W) and chemotherapy (SOX/XELOX Q3W) regardless of programmed death ligand-1 status in advanced gastric cancer and gastroesophageal junction cancer (GC/GEJC) patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Sintilimab (Primary) ; Capecitabine; Gimeracil/oteracil/tegafur; Oxaliplatin
Indications Gastric cancer; Oesophageal cancer
Focus Therapeutic Use

09 Jul 2024 New trial record
04 Jun 2024 Results (n=21) assessing predictive markers and potential mechanism of combination therapy for GC/GEJC in real-world settings based on blood proteomic biopsy, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com